Barbara Burton
Clinical Genetics (M.D.) · Chicago, ILNPI 1699743088
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 45.7% of the total.
Across 827 payments — averaging $921.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$348K
- Takeda Pharmaceuticals U.S.A., Inc.$113K
- Amgen$42K
- Sanofi-aventis U.S. LLC$41K
- Ultragenyx Pharmaceutical Inc.$37K
- Shire North American Group Inc$37K
- plus $144K from 17 others
Across 424 payments — averaging $13,529 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$3.3M
- Shire North American Group Inc$903K
- Ultragenyx Pharmaceutical Inc.$650K
- Biomarin Pharmaceutical Inc.$614K
- AstraZeneca$71K
- Modernatx, Inc.$59K
- plus $93K from 5 others
What the payments were for
- Consulting fees$250,77433%
- Speaking & faculty fees$338,45444%
- Travel & lodging$135,86018%
- Food & beverage$9,1241%
- Education$28,1464%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 476 | $348,038 |
| Takeda Pharmaceuticals U.S.A., Inc. | 62 | $112,698 |
| Amgen(2 entities) | 30 | $42,465 |
| Sanofi-aventis U.S. LLC | 13 | $40,995 |
| Ultragenyx Pharmaceutical Inc. | 17 | $37,307 |
| Shire North American Group Inc | 37 | $36,547 |
| PTC Therapeutics, Inc. | 31 | $32,692 |
| Sanofi | 33 | $28,820 |
| AstraZeneca | 32 | $22,617 |
| Modernatx, Inc. | 65 | $18,551 |
| Chiesi USA, Inc. | 10 | $12,005 |
| Travere Therapeutics, Inc. | 4 | $6,200 |
| Agios Pharmaceuticals, Inc. | 3 | $5,200 |
| Orchard Therapeutics North America | 3 | $5,057 |
| Pfizer | 1 | $3,230 |
| Amicus Therapeutics, Inc. | 1 | $3,000 |
| Mirum Pharmaceuticals, Inc. | 2 | $2,736 |
| NS Pharma, Inc. | 1 | $1,620 |
| Janssen Global Services, LLC | 1 | $975 |
| Vertex | 2 | $917 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $600 |
| Intrabio Inc | 1 | $51 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$202,076
- Kuvan$115,961
- ELAPRASE$57,623
- Vimizim$43,245
- NO PRODUCT DISCUSSED$40,155
- RAVICTI$37,950
- ALDURAZYME$23,576
- Naglazyme$12,776
- DISEASE STATE$10,292
- Kanuma$7,598
- Brineura$6,668
- DOJOLVI$6,400
- LENMELDY$5,057
- LAMZEDE$3,853
- (820) Cholbam$2,736
- XENPOZYME$2,303
- CERDELGA$300
- ELFABRIO$300
- FABRAZYME$134
- NEXVIAZYME$134
How this compares
Too few clinical genetics (m.d.) providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Chicago
- Carlos PradaChicago$303K
- Joshua BakerChicago$221K
- Joel CharrowChicago$189K
- William DobynsChicago$2K
- Susan EchiverriChicago$2K
- Miguel BarajasChicago$1K
- Brandon ChalazanChicago$603
- Gifty BhatChicago$149
- Mindy LiChicago$49
- George HogansonChicago$30
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.